Serum exosomal microRNA-34a as a potential biomarker in epithelial ovarian cancer

Maeda, Keiko; Sasaki, Hiroshi; Ueda, Satoshi; Miyamoto, Shunsuke; Terada, Shinichi; Konishi, Hiromi; Kogata, Yuhei; Ashihara, Kaoru; Fujiwara, Satoe; Tanaka, Yoshimichi; Tanaka, Tomohito; Hayashi, Masami; Ito, Yuko; Kondo, Yoichi; Ochiya, Takahiro; Ohmichi, Masahide

doi:10.1186/s13048-020-00648-1

Cited by 39 publications

(26 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…miRNA-21, miRNA-29a, miRNA-92, and miRNA-93 were significantly overexpressed in EOC serum samples compared to tissue samples, while other sets of miRs (miRNA-99b, miRNA-127, and miRNA-155) were underexpressed in serum samples compared to tissue samples of EOC patients (Resnick et al, 2009;Hausler et al, 2010;Deng et al, 2017). Maeda et al (2020) recently described the potential role of serum miRNA-34a in early diagnosis of ovarian cancer and for histological subtyping of EOC. The expression of serum miR-34a was significantly higher in ovarian carcinoma compared to normal control (Maeda et al, 2020).…”

Section: Blood-based Circulating Mirna As a Biomarker In Ovarian Cancmentioning

confidence: 99%

“…Maeda et al (2020) recently described the potential role of serum miRNA-34a in early diagnosis of ovarian cancer and for histological subtyping of EOC. The expression of serum miR-34a was significantly higher in ovarian carcinoma compared to normal control (Maeda et al, 2020). Similarly another study using High-throughput sequencing revealed 65 differentially expressed miRNAs (34 upregulated and 31 downregulated) in OC patients compared to healthy patients.…”

Section: Blood-based Circulating Mirna As a Biomarker In Ovarian Cancmentioning

confidence: 99%

See 1 more Smart Citation

microRNA as Biomarker in Ovarian Cancer Management: Advantages and Challenges

Kumar

Gupta

Varma

et al. 2020

DNA and Cell Biology

View full text Add to dashboard Cite

Ovarian cancer is the most prevalent gynecological malignancy affecting women throughout the globe. Ovarian cancer has several subtypes, including epithelial ovarian cancer (EOC) with a whopping incidence rate of 239,000 per year, making it the sixth most common gynecological malignancy worldwide. Despite advancement of detection and therapeutics, death rate accounts for 152,000 per annum. Several protein-based biomarkers such as CA125 and HE4 are currently being used for diagnosis, but their sensitivity and specificity for early detection of ovarian cancer are under question. microRNA (a small noncoding RNA molecule that participates in posttranscription regulation of gene expression) and its functional deregulation in most cancers have been discovered in the previous two decades. Studies support that miRNA deregulation has an epigenetic component as well. Aberrant miRNA expression is often correlated with the form of EOC tumor, histological grade, prognosis, and FIGO stage. In this review, we addressed epigenetic regulation of miRNAs, the latest research on miRs as a biomarker in the detection of EOC, and tailored assays to use miRNAs as a biomarker in ovarian cancer diagnosis.

show abstract

Section: Blood-based Circulating Mirna As a Biomarker In Ovarian Cancmentioning

confidence: 99%

Section: Blood-based Circulating Mirna As a Biomarker In Ovarian Cancmentioning

confidence: 99%

microRNA as Biomarker in Ovarian Cancer Management: Advantages and Challenges

Kumar

Gupta

Varma

et al. 2020

DNA and Cell Biology

View full text Add to dashboard Cite

show abstract

“…Ovarian cancer is the deadliest gynecological cancer in women; hence, the early detection and treatments are vitally important (40). Efforts have been taken to developed drugs to treat ovarian cancers overexpressing estrogen receptor (ER) and HER2.…”

Section: Pretargeted Theranostics In Ovarian Cancermentioning

confidence: 99%

Theranostic Pretargeting Drug Delivery and Imaging Platforms in Cancer Precision Medicine

Hapuarachchige

Artemov

2020

Front. Oncol.

View full text Add to dashboard Cite

Theranostics are nano-size or molecular-level agents serving for both diagnosis and therapy. Structurally, they are drug delivery systems integrated with molecular or targeted imaging agents. Theranostics are becoming popular because they are targeted therapeutics and can be used with no or minimal changes for diagnostic imaging to aid in precision medicine. Thus, there is a close relation between theranostics and image-guided therapy (IGT), and theranostics are actually a subclass of IGT in which both therapeutic and imaging functionalities are attributed to a single platform. An important theranostics strategy is biological pretargeting. In pretargeted IGT, first, the target is identified by a target-specific natural or synthetic bioligand followed by a nano-scale or molecular drug delivery component, which form therapeutic clusters by in situ conjugation reactions. If pretargeted drug delivery platforms are labeled with multimodal imaging probes, they can be used as theranostics for both diagnostic imaging and therapy. Optical and nuclear imaging techniques have mostly been used in proof-of-concept studies with pretargeted theranostics. The concept of pretargeting in theranostics is comparatively novel and generally requires a confirmed overexpression of surface receptors on targeted cells/tissue. In addition, the receptors should have natural or synthetic bioligands to be used as pretargeting components. Therefore, applications of pretargeting theranostics are still limited to several cancer types, which overexpress cell-surface markers on the target cancer cells. In this review, recent discoveries of pretargeting theranostics in breast, ovarian, prostate, and colorectal cancers are discussed to highlight main strengths and potential limitations the strategy.

show abstract

“…In contrast, miR-21 and miR-324 within these tumor-released exosomes were found to be strong neuritogenic signals [ 78 ]. miR-34a is a candidate biomarker for ovarian cancer and has been shown to correlate with tumor stage and aggression [ 79 ]. Additionally, miR-21 has been identified as a biomarker of chemotherapy response in esophageal, lung, pancreatic, and prostate cancers [ 80 , 81 , 82 , 83 ].…”

Section: Neurogenic and Oncogenic Trophic Factors As Biomarkers Ofmentioning

confidence: 99%

Interrupting Neuron—Tumor Interactions to Overcome Treatment Resistance

Hunt

Kabotyanski

Calin

et al. 2020

Cancers

View full text Add to dashboard Cite

Neurons in the tumor microenvironment release neurotransmitters, neuroligins, chemokines, soluble growth factors, and membrane-bound growth factors that solid tumors leverage to drive their own survival and spread. Tumors express nerve-specific growth factors and microRNAs that support local neurons and guide neuronal growth into tumors. The development of feed-forward relationships between tumors and neurons allows tumors to use the perineural space as a sanctuary from therapy. Tumor denervation slows tumor growth in animal models, demonstrating the innervation dependence of growing tumors. Further in vitro and in vivo experiments have identified many of the secreted signaling molecules (e.g., acetylcholine, nerve growth factor) that are passed between neurons and cancer cells, as well as the major signaling pathways (e.g., MAPK/EGFR) involved in these trophic interactions. The molecules involved in these signaling pathways serve as potential biomarkers of disease. Additionally, new treatment strategies focus on using small molecules, receptor agonists, nerve-specific toxins, and surgical interventions to target tumors, neurons, and immune cells of the tumor microenvironment, thereby severing the interactions between tumors and surrounding neurons. This article discusses the mechanisms underlying the trophic relationships formed between neurons and tumors and explores the emerging therapies stemming from this work.

show abstract

Serum exosomal microRNA-34a as a potential biomarker in epithelial ovarian cancer

Cited by 39 publications

References 43 publications

microRNA as Biomarker in Ovarian Cancer Management: Advantages and Challenges

microRNA as Biomarker in Ovarian Cancer Management: Advantages and Challenges

Theranostic Pretargeting Drug Delivery and Imaging Platforms in Cancer Precision Medicine

Interrupting Neuron—Tumor Interactions to Overcome Treatment Resistance

Contact Info

Product

Resources

About